Targeted Molecular Therapeutics for Bladder Cancer—A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted Molecular Therapeutics for Bladder Cancer—A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 19, Pages 7268
Publisher
MDPI AG
Online
2020-10-01
DOI
10.3390/ijms21197268
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer
- (2020) Kiera Roubal et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma
- (2020) Jonathan Rosenberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Study EV-103: New cohorts testing enfortumab vedotin alone or in combination with pembrolizumab in muscle invasive urothelial cancer.
- (2020) Christopher J. Hoimes et al. JOURNAL OF CLINICAL ONCOLOGY
- Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.
- (2020) Jonathan E. Rosenberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.
- (2020) Thomas Powles et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
- (2020) Matthew D Galsky et al. LANCET
- The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States
- (2020) Rachael Louise Slater et al. JOURNAL OF MEDICAL ECONOMICS
- Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275
- (2020) Matthew D. Galsky et al. CLINICAL CANCER RESEARCH
- Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer
- (2020) Jacqueline Vuky et al. JOURNAL OF CLINICAL ONCOLOGY
- NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
- (2020) Shilpa Gupta et al. Nature Reviews Urology
- Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
- (2019) Arnaud Scherpereel et al. LANCET ONCOLOGY
- Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study.
- (2019) Scott T. Tagawa et al. JOURNAL OF CLINICAL ONCOLOGY
- TROPHY-u-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy.
- (2019) Scott T. Tagawa et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
- (2019) Y Fradet et al. ANNALS OF ONCOLOGY
- Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors
- (2019) Rastilav Bahleda et al. CLINICAL CANCER RESEARCH
- CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma.
- (2019) Jonathan E. Rosenberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential
- (2019) Capucine Baldini et al. OncoTargets and Therapy
- Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
- (2019) Jonathan E. Rosenberg et al. JOURNAL OF CLINICAL ONCOLOGY
- EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors.
- (2019) Daniel Peter Petrylak et al. JOURNAL OF CLINICAL ONCOLOGY
- Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
- (2019) Yohann Loriot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087
- (2019) Robert Chen et al. BLOOD
- EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†
- (2019) J. Alfred Witjes et al. EUROPEAN UROLOGY
- Cost-effectiveness of pembrolizumab as first-line treatment of locally advanced or metastatic urothelial carcinoma ineligible for cisplatin-based therapy in the United States.
- (2019) Yizhen Lai et al. JOURNAL OF CLINICAL ONCOLOGY
- Inter-observer Reliability of Programmed Cell Death Ligand-1 Scoring Using the VENTANA PD-L1 (SP263) Assay in Non-Small Cell Lung Cancer
- (2019) Gareth H. Williams et al. Journal of Thoracic Oncology
- Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial
- (2019) Daniel P Petrylak et al. LANCET ONCOLOGY
- Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma
- (2019) Kirollos S. Hanna DRUGS
- Mechanisms of resistance to immune checkpoint inhibitors
- (2018) Russell W Jenkins et al. BRITISH JOURNAL OF CANCER
- Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer
- (2018) Michal Sarfaty et al. EUROPEAN UROLOGY
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
- (2018) Thomas Powles et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
- (2018) Manish R Patel et al. LANCET ONCOLOGY
- Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab
- (2018) Bharathi Vennapusa et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Abstract CT031: Updated efficacy and safety profile of durvalumab monotherapy in urothelial carcinoma
- (2018) Peter O'Donnell et al. CANCER RESEARCH
- Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210.
- (2018) Arjun Vasant Balar et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
- (2018) Shijie Ren et al. PHARMACOECONOMICS
- Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
- (2018) Sabine E. Grimm et al. PHARMACOECONOMICS
- Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer
- (2018) Viktoria Stühler et al. WORLD JOURNAL OF UROLOGY
- A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors
- (2018) Vivek Verma et al. Journal for ImmunoTherapy of Cancer
- Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
- (2017) Aditya Bardia et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
- (2017) Arjun V Balar et al. LANCET ONCOLOGY
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- Precision Medicine: Progress, Pitfalls, and Promises
- (2017) Patrick G. Pilié et al. MOLECULAR CANCER THERAPEUTICS
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum‐Containing Chemotherapy
- (2017) Yang‐Min Ning et al. ONCOLOGIST
- Targeting IL-5Rα with antibody-conjugates reveals a strategy for imaging and therapy for invasive bladder cancer
- (2017) Michel Paquette et al. OncoImmunology
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
- (2017) Thomas Powles et al. JAMA Oncology
- Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
- (2016) P. M. Challita-Eid et al. CANCER RESEARCH
- Urothelial carcinoma management in elderly or unfit patients
- (2016) Joaquim Bellmunt et al. EJC SUPPLEMENTS
- Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
- (2016) Christophe Massard et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Bladder cancer
- (2016) Ashish M Kamat et al. LANCET
- Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas
- (2016) Andreas H Scheel et al. MODERN PATHOLOGY
- Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2
- (2015) Stéphane Oudard et al. EUROPEAN JOURNAL OF CANCER
- Molecular biomarkers for predicting outcomes in urothelial carcinoma of the bladder
- (2014) Nikhil Sapre et al. PATHOLOGY
- Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986
- (2011) Maria De Santis et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression of Trop2 Cell Surface Glycoprotein in Normal and Tumor Tissues
- (2011) Lara P. Stepan et al. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
- Bladder cancer
- (2009) Donald S Kaufman et al. LANCET
- Antibody Conjugates of 7-Ethyl-10-hydroxycamptothecin (SN-38) for Targeted Cancer Chemotherapy
- (2008) Sung-Ju Moon et al. JOURNAL OF MEDICINAL CHEMISTRY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started